桑辛素通过抑制STAT3反馈激活增强MAPK通路抑制剂对BRAF突变黑色素瘤的抗肿瘤活性
本研究在细胞和动物水平验证桑辛素是否通过抑制STAT3反馈激活来增强MAPK通路抑制剂对BRAF突变黑色素瘤的抑制作用。结果显示桑辛素可增强MAPK通路抑制剂对BRAF突变黑色素瘤细胞的抑制效应,联合用药在体内外共同抑制BRAF突变及耐药黑色素瘤。作者认为桑辛素联合MAPK通路抑制剂可能比单用MAPK通路抑制剂更有效。
要点
- 桑辛素通过抑制STAT3/SOX2通路反馈激活增强MAPK通路抑制剂对BRAF突变黑色素瘤细胞的抑制作用。
- 桑辛素联合MAPK通路抑制剂对BRAF突变黑色素瘤细胞的抑制程度大于野生型细胞。
- 桑辛素与BRAF抑制剂联合在体内共同抑制BRAF突变黑色素瘤,并在体外和体内共同抑制耐药黑色素瘤。
核心结论
- 作者认为桑辛素联合MAPK通路抑制剂可能成为BRAF突变黑色素瘤比单用MAPK通路抑制剂更有效的治疗策略。
研究设计与样本
- 本研究在细胞和动物水平验证桑辛素是否通过抑制STAT3反馈激活增强MAPK通路抑制剂对BRAF突变黑色素瘤的抑制作用。
主要发现
- 桑辛素通过抑制STAT3/SOX2通路反馈激活增强MAPK通路抑制剂对BRAF突变黑色素瘤细胞的抑制作用。
- 桑辛素联合MAPK通路抑制剂对BRAF突变黑色素瘤细胞的抑制程度大于野生型细胞。
- 桑辛素与BRAF抑制剂联合在体内共同抑制BRAF突变黑色素瘤。
- 桑辛素与MAPK通路抑制剂联合在体外和体内共同抑制耐药黑色素瘤。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BRAF and MEK inhibitors significantly prolonged the progression-free survival of patients with BRAF mutant melanoma, but their long-term efficacy was limited by drug resistance. Our previous studies found that targeted inhibition of the mitogen-activated protein kinases (MAPK) pathway promotes the activation of the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway in BRAF-mutant melanoma cells. Whether dual inhibition of MAPK and JAK2/STAT3 pathways can reverse drug resistance in melanoma remains unclear. METHODS: This study verified whether morusin could enhance the inhibitory effect of MAPK pathway inhibitors on BRAF mutant melanoma by inhibiting the feedback activation of STAT3 at the cellular and animal levels. RESULTS: We demonstrated that morusin could enhance the inhibitory effect of MAPK pathway inhibitors on BRAF mutant melanoma cells by inhibiting the feedback activation of the STAT3/SOX2 pathway. Moreover, our study showed morusin combined with MAPK pathway inhibitors specifically inhibited BRAF-mutant melanoma cells to a greater extent than wild-type cells. Our results also showed that the combination of morusin and BRAF inhibitors could jointly inhibit BRAF mutant melanoma in vivo. Finally, our experiment also revealed that the combination therapy of morusin and MAPK pathway inhibitors jointly inhibited drug-resistant melanoma in vitro and in vivo. CONCLUSION: Our results suggested that the combination of morusin and MAPK pathway inhibitors may be a more effective treatment strategy for BRAF-mutant melanoma than MAPK pathway inhibitors alone.
引用
- Zhao K, Dai Q, Wu J, et al. Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3. Eur J Cancer. 2022. PMID: 35219024. doi:10.1016/j.ejca.2022.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。